TY - JOUR
AU1 - Välitalo, Pyry
AU2 - Kokki, Merja
AU3 - Ranta, Veli-Pekka
AU4 - Olkkola, Klaus
AU5 - Hooker, Andrew
AU6 - Kokki, Hannu
AB - Pharm Res (2017) 34:1125–1133 DOI 10.1007/s11095-017-2122-6 RESEARCH PAPER Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials 1 2,3 4 5 6 Pyry Välitalo & Merja Kokki & Veli-Pekka Ranta & Klaus T. Olkkola & Andrew C. Hooker & 2,3 Hannu Kokki Received: 9 December 2016 /Accepted: 9 February 2017 /Published online: 15 February 2017 # Springer Science+Business Media New York 2017 ABSTRACT maturation function. Central and peripheral volumes of dis- Purpose The aim of the current population pharmacokinetic tribution were nonlinearly related to bodyweight. The simu- study was to quantify oxycodone pharmacokinetics in children lations on repeated intravenous administration in virtual pa- ranging from preterm neonates to children up to 7 years of tients indicated that oxycodone plasma concentration can be age. kept between 10 and 50 ng/ml with a high probability when Methods Data on intravenous or intramuscular oxycodone the maintenance dose is calculated using the typical clearance administration were obtained from three previously published and the dose interval is 4 h. studies (n = 119). The median [range] postmenstrual age of Conclusions Oxycodone clearance matures rapidly after the subjects was 299 days [170 days-7.8 years]. A population birth, and 
TI - Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials
JF - Pharmaceutical Research
DO - 10.1007/s11095-017-2122-6
DA - 2017-02-15
UR - https://www.deepdyve.com/lp/springer-journals/maturation-of-oxycodone-pharmacokinetics-in-neonates-and-infants-a-W0JuVIG2Vc
SP - 1125
EP - 1133
VL - 34
IS - 5
DP - DeepDyve
ER -